TheraRadar
← Back
Data updated: Mar 29, 2026

ANNORA PHARMA

ImmunologyCardiovascularNeurology
Generics

ANNORA PHARMA is a generic drug manufacturer focused on Immunology, Cardiovascular, Neurology.

2002
Since
51
Drugs
-
Trials
709
Approved (2yr)

Key Drugs

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
diatrizoate meglumine
1 indications · 2022
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE
magnesium sulfate
· 2017

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
GABAPENTIN 2026-02-24
Labeling
LURASIDONE HYDROCHLORIDE 2026-02-24
Labeling
LURASIDONE HYDROCHLORIDE 2026-02-24
Labeling
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 29%
4 drugs
Cardiovascular 21%
3 drugs
Neurology 21%
3 drugs
Gastroenterology 14%
2 drugs
Infectious Disease 14%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Bristol-Myers Squibb big-pharma
Immunology, Gastroenterology, Infectious Disease, Neurology
Pfizer big-pharma
Infectious Disease, Immunology, Gastroenterology
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
AbbVie big-pharma
Immunology, Neurology, Infectious Disease
PAI HOLDINGS PHARM big-pharma
Infectious Disease, Neurology, Cardiovascular, Immunology